Residual IDH1-Mutant Tumor Cell Quantification Study

This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.

NCT Number	NCT07219199
Lead Sponsor	NYU Langone Health
Conditions	Glioma
Enrollment	105 participants
Start Date	2025-12
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-10-21